Tivozanib for the treatment of renal cell carcinoma

Expert Opinion on Pharmacotherapy
Matteo SantoniNicola Battelli

Abstract

Renal cell carcinoma (RCC) represents a heterogeneous group of cancers with distinct histological features, molecular alterations, prognosis, and response to therapy. Target agents directed against vascular endothelial growth factor and its receptor and mammalian target of rapamycin (mTOR) inhibitors have completely changed the landscape of RCC. However, the rate of complete response is still low, thus supporting the research of novel therapeutic agents. Area covered: The authors describe the chemical features of tivozanib, its pharmacodynamic and pharmacokinetic properties, and the results obtained in human phase I-III clinical trials. Tivozanib received its first global approval in EU, Iceland, and Norway on 28 August 2017 for the first-line treatment of adult patients with advanced RCC and for adult patients who are VEGFR and mTOR inhibitor-naive following disease progression after one prior treatment with cytokines. Expert opinion: The US Food and Drug Administration did not approve tivozanib due to the lack of a significant advantage in terms of survival compared to sorafenib. To date, the role of tivozanib in the pharmaceutical landscape of mRCC appears to be very limited. However, ongoing trials on the association betwee...Continue Reading

References

Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Feb 28, 2007·Critical Reviews in Oncology/hematology·Robert Roskoski
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Feb 13, 2009·Molecular Biology of the Cell·Nao HosokawaNoboru Mizushima
Aug 13, 2009·Current Pharmaceutical Design·Volker H Haase
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Oct 27, 2010·Annals of the New York Academy of Sciences·Helena PavlakovicJayakrishna Ambati
Oct 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ferry A L M EskensJaap Verweij
Apr 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dmitry A NosovPankaj Bhargava
Sep 19, 2012·Proceedings of the National Academy of Sciences of the United States of America·Michele McTigueRobert S Kania
Jun 4, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M N FishmanF F Kabbinavar
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerThomas E Hutson
Mar 19, 2015·Current Treatment Options in Oncology·Javier Puente VázquezJ L Gonzalez Larriba
Feb 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriMichael J Morris
Mar 17, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ana M MolinaTim Eisen

❮ Previous
Next ❯

Citations

Oct 31, 2019·Immunotherapy·Francesco MassariAntonio Lopez-Beltran
Nov 20, 2018·Frontiers in Oncology·Antonio Lopez-BeltranRodolfo Montironi
Apr 28, 2021·European Journal of Medicinal Chemistry·Xiaoxia LiangBo Jing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.